Check Point Research Articles

6410 Effects of Immune Check Point Inhibitors on Thyroid Function

Abstract Disclosure: V. Kachroo: None. S.K. Wangnoo: None. M.A. Siddiqui: None. Immune check point inhibitors (ICPIs) are the newest agents for the treatment of malignant tumors, showing promising effects and potential, and has immune related adverse events (IRAEs) as well. IRAEs involve various organs and tissues and also cause thyroid dysfunction. This is a non randomized prospective observational study done at a tertiary referral hospital in patients initiated on ICPIs for the underlying malignancies between March 2022 to September 2023. A total of 35 patients were taken after calculating the sample size using appropriate statistical formula. Thyroid function tests (T3, T4, TSH,) were done monthly for first six months and then every three-monthly till 12 months in patients not on any thyroid medication. In patients already getting treatment for hypothyroidism/hyperthyroidism,TSH was assayed monthly for 3 months, then every 3 months for 12 months. Anti TPO antibody levels were done at baseline and at 12 months in all the individuals. Overt and subclinical hyperthyroidism/ hypothyroidism was defined usinh standard criteria.The assay used for the determination of TSH, FT4, FT3 and anti-TPO Antibody was Chemiluminescent Immunoassay (CLIA). Normal reference ranges for TSH was 0.27-4.20 mU/ml, FT4 was 0.90-1.70 ng/dl and FT3 was 2.0- 4.4 pg/ml. Out of 35 patients, 24(68.5%) were males and 11 were females (31.4%). 25.71% already had history of thyroid dysfunction in the form of primary hypothyroidism and were on levothyroxine and no one had hyperthyroidism when they were initiated on ICPIs. Out of 9 patients, 6 patients had no change in dose (66.67%); 2 patients had increased dose requirement (22.22%) and 1 patient had decreased dose requirement (11.11%). Out of remaining 26 patients who didn’t have any thyroid function, 12(46.15%) had new onset thyroid dysfunction. All 26 had hypothyroidism (either overt or subclinical). Out of these 26 patients, 9(34.62%) had overt hypothyroidism and started on levothyroxine as per their age and body weight requirements, 3(11.54%) patients had subclinical hypothyroidism. Out of 12 patients, who developed new onset TDF after initiation of ICPIs, 2 patients became TPO positive and 10 patients had negative TPO Antibodies at the end of 12 months. Kaplan Meir analysis showed that thyroid dysfunction at the end of 3 months was in 13.33% of patients, in 53.85% each at the end of 6 months and 12 months. The mean time of onset of thyroid dysfunction was 3.083 months in (IQR=2.25-3.917 months; 95% CI; SE=0.379). We conclude that thyroid dysfunction in the form of new onset hypothyroidism (subclinical or overt) or increased thyroxine dose requirement in the patient who are already hypothyroid is seen in patients receiving ICPIs. Regular surveillance of thyroid function is warranted in patients receiving these drugs. Presentation: 6/3/2024

Analysis of Financial Performances for CHKP: Comparison with QLYS, RPD and GEN

Due to the escalating cyber threats, the cybersecurity industry has experienced significant growth, necessitating a detailed financial performance study of market leaders to provide a comprehensive picture of company health and market position. This study investigates the financial performance of four leading cybersecurity companies: Check Point Software Technologies Ltd. (CHKP), Qualys Inc. (QLYS), Rapid7 Inc. (RPD), and Gen Digital Inc. (GEN) over the period from 2019 to 2024. The analysis reveals that Check Point consistently maintains high margins and stable profitability, making it the best investment among the four. In contrast, Qualys, Rapid 7, and Gen Digital show less competitive performance due to various operational and profitability challenges. The study acknowledges its limitations, including reliance on quantitative metrics and a limited timeframe, but underscores the promising prospects for the cybersecurity industry driven by the increasing need for advanced digital security solutions. These results provide valuable insights for investors and stakeholders in making informed decisions in the dynamic cybersecurity sector.

Peran Aviation Security dalam Pengawasan dan Penanganan Dangerous Goods dan Prohibited Item di Bandar Udara Tjilik Riwut Palangka Raya

Tjilik Riwut Palangka Raya Airport is the largest airpot in Central Kalimantan Privince. This airport has a runway size of 2,500 x 45cm. this airport is managed by PT.Angkasa Pura II. Aviation Security (AVSEC) based on the regulation of the Director General of Air Transportation with Number: SKEP 2756/XII/2010 concerning procedures for checking the security of passengers,aircraft officers,and luggage transported by aircraft and individuals. Thes purpose of this study is to determine the differences between Security Check Point1 and Security Check Point 2 and to determine the work system of supervision and handling of Dangerous Goods and Prohibited Item at Tjilik Riwut Palngka Raya Airport. This research is a qualitative research with data collection techniques,namely observasion,documentation,and interview. Data analysis techniques used are data collection,data reduction,data presentasion, and drawing conclusions. The results of the research conducted by the researcher showed that there was nosignificant difference between Security Check Point 1 and Security Check Point 2 and the work system of Aviation Security officers was in accordance with existing procedures in the supervision and handling of Dangerous Goods and Prohibited Item.

The Influence of Security Check Point (SCP) 2 Security Inspection Services on Passenger Satisfaction at the Aviation Security Unit (AVSEC) of Adi Soemarmo Boyolali International Airport

The Influence of Security Check Point (SCP) 2 Security Inspection Services on Passenger Satisfaction at the Aviation Security Unit (AVSEC) of Adi Soemarmo Boyolali International Airport

The Implementation of Cambridge Curriculum in English Learning at SMP Lazuardi Tursina

In Indonesian schools, the curriculum is crucial for teaching-learning process. As a means of improving student competencies and educational quality, certain Indonesian schools are starting to implement overseas curricula, such as Cambridge. However Indonesian schools have different approaches to implementing the Cambridge curriculum. The purpose of this research is to investigate how the Cambridge Curriculum is being used at SMP Lazuardi Tursina for English language instruction. A qualitative strategy using a case study design is the methodology used. Data were gathered using curriculum-related document analysis, interviews, and observations. The results show three important phases to the Cambridge curriculum's application in English learning: planning, implementing, and assessing. With a focus on critical thinking and problem-solving techniques, SMP Lazuardi Tursina combines the Independent and Cambridge curricula. Adapting to Project-Based Learning and Learning Experience Design, as well as instructor turnover, are implementation challenges. The learners' progress and performance were assessed using the Check Point and Cambridge Progression Tests. The findings highlight how important the phases of the Cambridge curriculum implementation are to SMP Lazuardi Tursina's successful adoption of the curriculum. To support student learning outcomes and improve educational quality, the Cambridge curriculum demands careful planning, creative teaching strategies, and thorough evaluation.

Drug-induced cholestatic liver diseases.

Cholestatic DILI is an important and frequently challenging differential diagnosis in patients presenting with elevated liver tests with predominant elevation in alkaline phosphatase. A number of competing etiologies need to be ruled out, such as hepatobiliary malignancy, choledocholithiasis, cholestatic forms of viral hepatitis, cholestasis of sepsis, primary and secondary cholangitis, and right-sided cardiac failure to name a few. Important advances have occurred in the understanding and knowledge of the clinical phenotypes, new etiological agents, risk factors, pathophysiology, and genetic determinants of drug-induced cholestasis since the last review on drug-induced cholestasis was published in Hepatology in 2011. Secondary sclerosing cholangitis (SSC) due to drugs has been well documented for several different drugs. Checkpoint inhibitors are one of the types of drugs shown to lead to secondary sclerosing cholangitis. Several new herbal and dietary supplements have recently been shown to lead to cholestatic liver injury. A number of genetic risk factors for cholestasis due to drugs have been identified in the last decade, and the pathogenesis behind cholestatic injury is better defined. In this review, the focus is on diagnostic approach and description of new clinical phenotypes such as secondary sclerosing cholangitis and vanishing bile duct syndrome. Furthermore, the review provides an overview of the risk factors, genetic determinants, and the pathophysiology of hepatobiliary transporters leading to cholestasis. Management, areas of uncertainty, and future direction are also presented.

ROLE OF HAEMATOLOGY BIOMARKERS IN URINARY BLADDER AND RENAL CELL CANCER PATIENTS TREATED WITH IMMUNE-ONCOLOGICAL DRUGS

Background: Urinary bladder (UB) and Renal Cell Cancer (RCC) are common in men than women with poor outcome. The novel immunotherapy drugs like Immune Check Point Inhibitors (ICIs) are effective but expensive. However, a cost-effective and reliable biomarker to predict response and clinical outcomes is lacking. Objective: To study the association of pre-treatment haematological parameters with clinical outcome in urinary bladder and renal cell cancer patients treated with ICIs. Method: In a retrospective study, we included 52 patients with urinary bladder and RCC treated with ICIs from Jan 2008 to Dec 2019. Clinical evaluation and laboratory investigations were performed as a part of standard protocol. CBC parameters such as WBC, TLC, DLC, Hb, Platelet, Neutrophil:Lymplocyte Ratio(NLR), Platelet:Lymphocyte Ratio (PLR), Lymphocyte:Monocyte Ratio(LMR) were studied at the time of TMC enrolment(first) and before the start (pre-treatment) of the ICIs therapy(io). Results: Amongst the CBC parameters, WBC count, when categorized based on cut off from ROC at the time of TMC enrolment(first) and the pre-treatment of the ICIs therapy(io) were found to be significantly associated with progression of disease with p- value 0.012 with Hazard Ratio (HR) - 2.52 (95% C.I. - 1.2-5.31) & p- value 0.060 with Hazard Ratio (HR) – 1.99 (95% C.I. – 0.96-4.12) respectively. The ROC - based cut off for WBC at the time of TMC enrolment(first) and the pre-treatment of the ICIs therapy(io) were found to be 7.16 X10e3/µL (AUC of 72%) with 71% sensitivity and 72% specificity and 6.48 X10e3/µL (AUC of 74%) with 67% sensitivity and 72% specificity respectively to predict progressed cases with respect to non-progressed cases. Along with WBC, the pre-treatment Absolute Neutrophil Count (ANC) (>3.67)& Absolute Monocyte count (AMC)(>0.42) pre-treatment of the ICIs therapy(io)) showed a significance with Hazard Ratio (HR) – 3.09(95% C.I.– 1.26-7.6) with p-value 0.010, Hazard Ratio (HR) – 3.48(95% C.I. - 1.6-7.57)and p-value <0.001 respectively. The ROC- based cut off for ANC at the pre-treatment of the ICIs therapy(io) were found to be 3.67 X10e3/µL (AUC of 68.4%) with 82.4% sensitivity and 50% specificity. Similarly The ROC- based cut off for AEC at the time of TMC enrolment(first) and AMC at the pre- treatment of the ICIs therapy(io) were found to be 0.22 X10e3/µL (AUC of 69.6%) with 55.9% sensitivity and 82.3% specificity and 0.42 X10e3/µL (AUC of 74.7%) with 72.7% sensitivity and 72.2% specificity respectively to predict progressed cases compared to non-progressed cases. Of 52 patients, 34 (65.4%) had progression. The median (m) PFS was 8.67 months (95% CI 2.26 - 15.09).The one year PFS rate was 46.5 (95% CI 31.2 -60.5). The mPFS in WBC <=7.16 was 26.48 months (95% CI 0 - 53.08) higher than the mPFS of 5.75 (95% CI 0.21 - 11.29) in WBC >7.16 with P value 0.012 at the time of TMC enrolment. Similarly, the mPFS in WBC pre- treatment of the ICIs therapy(io))<=6.48 was13.11 months (95% CI 0 – 28.95) higher than the mPFS of 6.18 (95% CI 2.67-9.68) in WBC >6.48 with P value 0.060.Along with WBC, the mPFS in ANC at the pre- treatment of the ICIs therapy(io)<=3.67 was 27.4(95% CI 0-55.21) higher than the mPFS of 6.18(95% CI 1.47-10.88)in ANC >3.67 with p value 0.010. The mPFS in AMC at the pre-treatment of the ICIs therapy(io)< =0.415 was 27.4 (95% CI 9.41-45.39) higher than the mPFS of 3.91 (95% CI 0.06-7.76) in AMC >0.415with p- value <0.001.We observed mPFS in immunotherapy cycles >=6 to be 15.9 (95% CI 6.98-24.82) was higher than the mPFS of 2.23 (95% CI 0.99-3.481) in immunotherapy cycles<6 with p value 0.025. The patients were followed for a period of 40.35 months (95% CI 26.98 - 53.71). Of 52 patients, 32(61.5%) patients deceased with median OS of 18.46 months (95% CI 10.12 - 26.80) and the one year OS rate was 57.6 (95% CI 41.6 - 70.6). Conclusion: Simple, routinely available and cost effective WBC (TLC), Absolute Neutrophil Count (ANC) ,Absolute Monocyte Count (AMC) and Absolute Eosinophil Count (AEC) from CBC test has a great potential to be used as a biomarker to predict response and clinical outcomes in patients with urinary bladder cancer and RCC patients treated with ICIs.

Evolutionary Trend Analysis of Research on Immunotherapy for Brain Metastasis Based on Machine-Learning Scientometrics.

Brain metastases challenge cancer treatments with poor prognoses, despite ongoing advancements. Immunotherapy effectively alleviates advanced cancer, exhibiting immense potential to revolutionize brain metastasis management. To identify research priorities that optimize immunotherapies for brain metastases, 2164 related publications were analyzed. Scientometric visualization via R software, VOSviewer, and CiteSpace showed the interrelationships among literature, institutions, authors, and topic areas of focus. The publication rate and citations have grown exponentially over the past decade, with the US, China, and Germany as the major contributors. The University of Texas MD Anderson Cancer Center ranked highest in publications, while Memorial Sloan Kettering Cancer Center was most cited. Clusters of keywords revealed six hotspots: 'Immunology', 'Check Point Inhibitors', 'Lung Cancer', 'Immunotherapy', 'Melanoma', 'Breast Cancer', and 'Microenvironment'. Melanoma, the most studied primary tumor with brain metastases offers promising immunotherapy advancements with generalizability and adaptability to other cancers. Our results outline the holistic overview of immunotherapy research for brain metastases, which pinpoints the forefront in the field, and directs researchers toward critical inquiries for enhanced mechanistic insight and improved clinical outcomes. Moreover, governmental and funding agencies will benefit from assigning financial resources to entities and regions with the greatest potential for combating brain metastases through immunotherapy.

Use of immunotherapy with check point inhibitors in soft tissue sarcoma: Analysis from single institution.

e23566 Background: Traditional treatments for soft tissue sarcomas include surgery, chemotherapy, and radiation. Effectiveness of Check point inhibitors for sarcoma has been unsatisfactory thus far. Major clinical trials PEMBROSARC and SARC028 revealed median PFS of 2 and 4.5 months, respectively. The FDA has approved three immunotherapy (IO) therapies for sarcoma. Atezolizumab was approved for alveolar soft part sarcoma. Dostarlimab is approved for sarcoma with DNA mismatch repair deficiency (dMMR), Sarcoma patients with high microsatellite instability (MSI-H), dMMR, or tumor mutational burden can receive pembrolizumab. A single-institution analysis of soft tissue sarcoma patients with IO is presented in this paper. Methods: All soft tissue sarcoma patients who have received IO from January 2021 to now have been included. At our institute, a total of seven patients received IO for soft tissue sarcoma. Observations were made regarding their fundamental characteristics and the progression free survival (PFS). The data was not statistically examined due to the small sample size and the heterogeneity of the data. Results: 2 of 7 trial patients were lost to follow-up. Recurrent autoimmune hepatitis terminated IO for another patient. Most of the patients are elderly with the median age of 78. Given their comorbidities and age, IO was chosen as the first line for 5 patients. Median PFS was 5.8 months. High PDL1 ( > / = 5%) patients had a median PFS of 5.6 months, while low PDL1 patients had 4.5 months. However, one patient with low PDL1 had PFS of 7 months. 5/7 patients didn’t have IO related side effects. Two patients developed Autoimmune (AI) hepatitis. Conclusions: The limited sample size prevented definitive conclusions from being drawn. Despite the unsatisfactory outcomes, it is worth mentioning that IO provided a certain degree of PFS in older patients with comorbidities who are not suitable candidates for chemotherapy. Based on limited data, patients with high PDL1 status appear to benefit more. IO alone has not shown promising results. In clinical trials, IO is being tested with chemotherapy and Tyrosine kinase inhibitors. The findings from these trials will provide valuable insights into the potential benefits of combination therapy. [Table: see text]

Serum Neurofilament Light Chain (sNfL) as Potential Biomarker for Immune Check Point Inhibitor (ICI) Mediated Limbic Encephalitis – A Case Series (P6-5.025)

Serum Neurofilament Light Chain (sNfL) as Potential Biomarker for Immune Check Point Inhibitor (ICI) Mediated Limbic Encephalitis – A Case Series (P6-5.025)

(361) - Soluble Immune Check Point Receptors Could be Feasible Markers of Rejection in Lung Transplanted Patients?

(361) - Soluble Immune Check Point Receptors Could be Feasible Markers of Rejection in Lung Transplanted Patients?

The Role of Immune Check Point Gene Expression of Pd-1 and Tim-3 in Patients with Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a hematopoietic cell cancer that spreads quickly to the blood and rapidly developing in the bone marrow. The prognosis for patients with acute myeloid leukemia (AML) is still poor, despite recent improvements in the therapeutic landscape. In hematological malignancies, immune checkpoint inhibitors have been studied, such as AML; however, the role of program cell death -1(PD-1) and T-cell immunoglobulin and mucin domain 3 (TIM3) in AML has not been thoroughly elucidated yet. Thus, the current study conducted to investigate the PD-1 and TIM‑3 gene expression in the AML patients and determine its associations with clinical outcomes and prognostic variables. The study collected 80 blood samples from acute myeloid leukemia (AML) patients and 40 blood samples from volunteer healthy individual were evaluated as control and real time quantitative (qRT-PCR) analysis was detect to performed PD-1 and TIM‑3 expression. The result showed there was non-significant (P>0.0001) in expression of TIM-3 in patients with AML, while expression of PD-1 statistically has high significant difference (P ≤ 0.0001). A cutoff value of PD-1 for patients vs. control was (0.853) with high sensitivity than cutoff value of TIM-3 for patients vs. control that can be diagnostically significant in distinguishing between patients and controls. Our data result showed that high expression of PD-1 in T cell is extremely correlated with progression of disease and down regulated gene expression of TIM-3 in AML patients.

Standardized production of hPSC-derived cardiomyocyte aggregates in stirred spinner flasks.

A promising cell-therapy approach for heart failure aims at differentiating human pluripotent stem cells (hPSCs) into functional cardiomyocytes (CMs) in vitro to replace the disease-induced loss of patients' heart muscle cells in vivo. But many challenges remain for the routine clinical application of hPSC-derived CMs (hPSC-CMs), including good manufacturing practice (GMP)-compliant production strategies. This protocol describes the efficient generation of hPSC-CM aggregates in suspension culture, emphasizing process simplicity, robustness and GMP compliance. The strategy promotes clinical translation and other applications that require large numbers of CMs. Using a simple spinner-flask platform, this protocol is applicable to a broad range of users with general experience in handling hPSCs without extensive know-how in biotechnology. hPSCs are expanded in monolayer to generate the required cell numbers for process inoculation in suspension culture, followed by stirring-controlled formation of cell-only aggregates at a 300-ml scale. After 48 h at checkpoint (CP) 0, chemically defined cardiac differentiation is induced by WNT-pathway modulation through use of the glycogen-synthase kinase-3 inhibitor CHIR99021 (WNT agonist), which is replaced 24 h later by the chemical WNT-pathway inhibitor IWP-2. The exact application of the described process parameters is important to ensure process efficiency and robustness. After 10 d of differentiation (CP I), the production of ≥100 × 106 CMs is expected. Moreover, to 'uncouple' cell production from downstream applications, continuous maintenance of CM aggregates for up to 35 d in culture (CP II) is demonstrated without a reduction in CM content, supporting downstream logistics while potentially overcoming the requirement for cryopreservation.

Introduction to the 9th edition of TNM classification for lung cancer

Lung cancer is the second commonly diagnosed cancer and remained the leading cause of cancer-related death, with an estimated 1.8 million deaths in 2020. The identification of driver gene mutation and administration of corresponding tyrosine kinase inhibitor have improved overall survival and quality of life in advanced lung cancer patients. Check point inhibitor has revolutionized treatment strategy of driver gene negative advanced NSCLC patients. TNM staging system is the most widely used classification method, providing an international common language during academic communication and important tool for predicting prognosis and subsequent treatment decision making. Accumulating knowledge about prognostic factors in lung cancer promotes the update of TNM classification. In the World Conference on Lung Cancer (WCLC) held in Singapore, September, 2023, International Association for Study of Lung Cancer (IASLC) released the forthcoming 9th edition of TNM classification for lung cancer, which is supposed to be adopted at January, 2024. The manuscript discussed the history, data resource and limitation of the TNM staging system.

Abstract 2507: Drivers of immunotherapy response within the CPI3000+ cohort

Abstract Introduction: Multiple genomic and transcriptomic biomarkers have been associated with response to immune checkpoint (CPI) therapy. These markers include tumor mutational burden (TMB), immune infiltration and HLA loss of heterozygosity. Our previously published meta-analysis of biomarkers included over 1000 patients (CPI1000) across multiple cancer types and demonstrated that clonal TMB and CXCL9 expression were the strongest predictors of response pan-cancer. Biomarkers were combined into a multivariable predictor of response which out-performed TMB in three validation cohorts. However, even with an extensive systematic review, the literature and exploratory biomarkers only accounted for ~60% of the variance explained in CPI response. Approach and Results: Extending the cohort to over 3000 patients from 20 studies, across 11 tumor solid tumor types, we have utilized available genomic and transcriptomic data to further validate the multi-variable predictor of response as well as conduct additional exploratory analysis to uncover the remaining variance explained. The raw data is processed through a robust bioinformatics pipeline and is harmonized across studies. The pipeline developed to process the CPI3000+ cohort will be open-access and available to promote federated learning and collaborations. Firstly, we have expanded the systematic review to include recent biomarkers from literature. The literature review included over 1000 papers, and we identified greater than 200 unique biomarkers which can be quantified and assessed in the CPI3000+ cohort. Data presented on this extensive set of genomic and transcriptomic biomarkers across the cohorts will improve understanding of biomarkers of response to CPI therapy. Second, we will explore novel biomarkers of response including non-classical sources of antigen such as retained introns as well as pathways such as the unfolded protein response. We will also survey the effects of tumor-associated antigens such as those involved in CAR-T cell and vaccine trials in CPI response which was limited in the CPI1000 cohort. We will also be presenting data on emerging checkpoints in late-stage trials across cancer types. Finally, we will be combining the biomarkers into a novel multivariable predictor of response. Conclusions: Results from this work will highlight the varying determinants of immunotherapy response across solid tumor types, offering insight into tumor intrinsic and extrinsic drivers of immunogenicity. We have shown that sources of tumour antigen are a major group of biomarkers for CPI response, here we expand on this further in a larger cohort as well as identifying novel biomarkers to create an improved multivariable predictor of clinical value. Citation Format: Krupa Thakkar, Andrea Castro, Danwen Qian, Charles Swanton, Kevin Litchfield. Drivers of immunotherapy response within the CPI3000+ cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2507.

The Influence of Check Point Unit Aviation Security (AVSEC) Security Services on Passenger Satisfaction at Yogyakarta International Airport

Licensed aviation security officers, known as Aviation Security, are responsible for managing and providing security services at airports. One of the main roles of Aviation Security (AVSEC) is to ensure the quality of security services at the Yogyakarta International Airport Security Check Point (SCP) for passengers. In research conducted in the November-December 2022 period at YIA Airport, it was found that a number of Avsec officers were still not friendly enough in providing services to consumers. The aim of this research is to understand the impact of the quality of Security Check Point security services by AVSEC officers on the level of passenger satisfaction at Yogyakarta International Airport. Apart from that, this research also aims to assess the extent to which the quality of Security Check Point security services by AVSEC officers influences passenger satisfaction at Yogyakarta International Airport. This research adopted a quantitative approach and was carried out at Yogyakarta International Airport. Respondents in this study consisted of fifty aviation security officers. To collect data, researchers used observation, questionnaires and documentation methods. Data management is carried out through simple linear regression analysis

Pengaruh Pengetahuan Penumpang tentang Prohibited Items terhadap Kepatuhan pada Security Check Point di Bandar Udara Internasional Adi Soemarmo Boyolali Jawa Tengah

In accordance with Law No. 1 of 2009 the purpose of the implementation of flights is to realize the operation of flights that are safe, secure, fast, smooth, orderly, orderly and comfortable. Passenger concern can be in the form of knowledge and compliance with aviation security and safety procedures, especially during security checks at the Security Check Point. Therefore, this study aims to determine the effect of passenger knowledge on compliance. This study uses three independen variabels, namely Analytical Thinking Knowledge (X1), Conceptual Thinking (X2) and Expertise (X3) for the dependen variabel, namely Compliance (Y) using a quantitative method that uses a questionnaire to collect data that is distributed directly to 100 passengers at Adi Soemarmo airport using a non-probability sampling technique which was then assisted by using the SPSS data processing application Version 20. This research was conducted at Adi Soemarmo International Airport Boyolali, Central Java on December 5 2022 to January 5 2023. The results of this study indicate that the Analytical Thinking (X1) and Expertise (X3) variabels have an influence on the Compliance variabel (Y) while the Conceptual Thinking variabel (X2) has no effect on the Compliance variabel (Y) as evidenced by the t test. The f test shows that the effect of passenger knowledge on compliance is 40.2%. Keywords: Knowledge, Analytical Thinking, Conceptual Thinking, Expertise, Compliance

Kiosk 5R-TA-01 - Left Atrial Evaluation in Immune Check Point Inhibitor Myocarditis Using Cardiac Magnetic Resonance Imaging and Correlations with Cardiovascular Outcomes

Kiosk 5R-TA-01 - Left Atrial Evaluation in Immune Check Point Inhibitor Myocarditis Using Cardiac Magnetic Resonance Imaging and Correlations with Cardiovascular Outcomes

Abstract A005: Preclinical evaluation of novel immune cell therapies, check point inhibitors, and immune cell engagers in humanized mouse models

Abstract Background The preclinical evaluation of novel immune therapies requires humanized mouse models with functional human immune cells. In previous studies we have demonstrated, that either peripheral blood mononuclear cells (PBMC), subsets of PBMCs like T- and NK-cells or hematopoietic stem cells (HSC) can be used to establish a humanized immune system with functional T-, B-, and NK cells, as well as monocytes and dendritic cells in immunodeficient mice. By xenotransplantation of cell-line-derived (CDX) or patient-derived (PDX) tumors on humanized mice, we successfully generated a full human tumor-immune-cell model for different disease entities. Finally, we validated the functionality of these models using checkpoint inhibitors like Ipilimumab (Ipi), Nivolumab (Nivo), Pembrolizumab (Pembro), cell therapies, and immune cell engagers. Methods HSC-humanized mice were generated by i.v. transplantation of CD34+ stem cells to immunodeficient 1st and 2nd generation NOG mice. Engraftment of immune cells was monitored by FACS analysis of blood samples. PBMC or isolated T- or NK-cell preparations were used to humanize mice by single or multiple i.v. injections. CDX and PDX from different entities were s.c. (i.e. lymphoma) and/or i.v. (leukemia) transplanted on those humanized mice. Tumor growth of orthotopic models was followed up by BLI measurement. Blood and tumor samples were analysed by for immune cell infiltration and activation. Results The transplanted HSCs engrafted in mice and established a functional human immune system with proliferation and differentiation. The 2nd generation NOG mice are showing an increased total engraftment and lineage specific differentiation of cells. The selected CDX and PDX tumors successfully engrafted on humanized mice without significant differences in tumor growth compared to non-humanized mice. Check point inhibitor treatments (Ipi, Nivo, or Pembro) induced tumor growth delay in selected models. BLI measurement is a suitable method to follow up systemic disease models and treatment effects over time. We identified a set of CDX and PDX models without interference with parallel injection of PBMC, T- or NK-cell preparations for the evaluation of immune cell engagers and other cell therapies. Conclusions We established human tumor-immune-cell models of different entities using CDX or PDX in combination with different donor derived immune cell subsets as effector cells. We demonstrated successful engraftment of HSC on different immunodeficient mouse strains, generating mice with a functional human hematopoiesis. These models have been successfully used for preclinical evaluation of novel check point inhibitors, cell therapies and immune cell engagers. Our human tumor-immune-cell models allow preclinical translational research on tumor immune biology as well as evaluation of new therapies, drug combinations, as well as biomarker identification and validation in subcutaneous and orthotopic models. Citation Format: Maria Stecklum, Annika Wulf-Goldenberg, Bernadette Brzezicha, Joshua Alcaniz, Glenn Smits, Wolfgang Walther, Jens Hoffmann. Preclinical evaluation of novel immune cell therapies, check point inhibitors, and immune cell engagers in humanized mouse models [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr A005.

THE NUMBER OF AVIATION SECURITY PERSONNEL ON SECURITY CHECK POINT 2 SERVICES

Minangkabau International Airport is one of the air transportation gateways in Padang Pariaman Regency, West Sumatra. When the author conducted research during On the Job Training at Minangkabau International Airport, the author saw that the number of Aviation Security personnel at Security Check Point 2 was not in accordance with existing regulations. Effective and efficient security services at the airport are very important to maintain passenger safety and prevent threats to flight safety. One factor that affects the quality of security services is the number of personnel available to carry out security tasks at the Security Check Point. The purpose of this study was to determine the effect of the number of Aviation Security personnel on Security Check Point 2 services at Minangkabau International Airport which is important to support passenger safety and comfort and realize excellent service quality for Minangkabau International Airport. This research method uses a quantitative descriptive method by making observations at Minangkabau International Airport, then obtaining data by distributing questionnaires to organic Aviation Security Personnel and service users. The results of this study indicate that service users agree that the number of Aviation Security personnel affects service. The problems in this study are expected to be used to make policies in improving the quality of security services at the airport